^
Association details:
Biomarker:GDF15 overexpression
Cancer:Oral Cancer
Regimen: (5-fluorouracil + cisplatin + docetaxel)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Elevated growth differentiating factor 15 expression predicts long-term benefit of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy in patients with oral cancer

Excerpt:
Furthermore, the cT3/4N0M0 patients with high GDF15 expression benefited significantly from TPF induction chemotherapy, including overall survival (HR=0.233; P=0.02), disease‑free survival (HR=0.296; P=0.014), locoregional recurrence‑free survival (HR=0.347; P=0.035) and distant metastasis‑free survival (HR=0.212; P=0.013) rates.
DOI:
10.3892/ol.2018.8324
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Mechanism of sensitivity to cisplatin, docetaxel, and 5-fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression

Published date:
12/21/2021
Excerpt:
The results indicated that OSCC cells overexpressing GDF15 were sensitive to TPF through a caspase-9-dependent pathway both in vitro and in vivo....When OSCC cells with GDF15 overexpression were treated with the erbB2 phosphorylation inhibitor, CI-1033, cell proliferation and xenograft growth colony formation were significantly blocked (P < .05)....Thus, ErbB2 inhibitors could represent potential targeted drugs or an alternative therapy for OSCC patients with GDF15 overexpression.
DOI:
10.1111/cas.15218